Alaunos Therapeutics, Inc. (TCRT)

NASDAQ: TCRT · IEX Real-Time Price · USD
0.523
0.021 (4.18%)
May 27, 2022 11:58 AM EDT - Market open
Market Cap112.96M
Revenue (ttm)398,000
Net Income (ttm)-66.99M
Shares Out215.95M
EPS (ttm)-0.32
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume826,083
Open0.520
Previous Close0.502
Day's Range0.480 - 0.547
52-Week Range0.410 - 3.730
Beta1.57
AnalystsBuy
Price Target3.88 (+641.7%)
Earnings DateMay 16, 2022

About TCRT

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc....

IndustryBiotechnology
Founded1998
Employees41
Stock ExchangeNASDAQ
Ticker SymbolTCRT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for TCRT stock is "Buy." The 12-month stock price forecast is 3.88, which is an increase of 641.73% from the latest price.

Price Target
$3.88
(641.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American ...

HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progr...

19 hours ago - GlobeNewsWire

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications

1 week ago - GlobeNewsWire

Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference

HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S. Boy...

2 weeks ago - GlobeNewsWire

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended March ...

2 weeks ago - GlobeNewsWire

Penny Stocks With Huge Potential According To 4 Wall Street Analysts

Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Infor...

Other symbols:BTTXMNMDSUNW
3 weeks ago - PennyStocks

What Makes Ziopharm (TCRT) a New Buy Stock

Ziopharm (TCRT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago - Zacks Investment Research

Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presenta...

3 weeks ago - GlobeNewsWire

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tu...

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that the first pa...

3 weeks ago - GlobeNewsWire

Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now

Short squeeze penny stocks to watch. The post Penny Stocks To Buy?

1 month ago - PennyStocks

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial resul...

1 month ago - GlobeNewsWire

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended Dec...

2 months ago - GlobeNewsWire

Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Compa...

2 months ago - GlobeNewsWire

Ziopharm Rebrands As Alaunos Therapeutics

The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow.

4 months ago - Benzinga

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted recent operatio...

4 months ago - GlobeNewsWire

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

The clinical-stage biotech saw a slight bounce-back from its lows of last week.

4 months ago - The Motley Fool

ZIOPHARM Oncology (ZIOP) Sees Hammer Chart Pattern: Time to Buy?

ZIOPHARM Oncology (ZIOP) has been struggling lately, but the selling pressure may be coming to an end soon.

6 months ago - Zacks Investment Research

Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Can...

HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation of preclinical data highlighting the potential of neoant...

6 months ago - GlobeNewsWire

Ziopharm Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced financial results for the third quarter ended September 30, 2021 and prov...

6 months ago - GlobeNewsWire

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended Septemb...

6 months ago - GlobeNewsWire

Best Penny Stocks To Buy Right Now? 3 Short Squeeze Stocks To Watch

Are short squeeze penny stocks part of your Q4 strategy? The post Best Penny Stocks To Buy Right Now?

Other symbols:FTFTKPLT
7 months ago - PennyStocks

Ziopharm (ZIOP) Down on Workforce Reduction Announcement

Ziopharm's (ZIOP) stock price falls after the announcement of several restructuring changes to advance the TCR program.

7 months ago - Zacks Investment Research

Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%

Ziopharm Oncology Inc (NASDAQ: ZIOP) announced a restructuring enabling the Company to advance its TCR program.  The Company will eliminate approximately 60 positions and expects the changes will extend...

7 months ago - Benzinga

Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway

• Over 50% reduction in personnel

7 months ago - GlobeNewsWire

Here's Why Ziopharm Oncology Stock Is Up 18% This Week

Recent insider stock purchases were more than a little encouraging.

8 months ago - The Motley Fool

Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?

Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research